Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 10 February 2004
Vol. 2004, Issue 219, p. tw47
[DOI: 10.1126/stke.2192004TW47]

EDITORS' CHOICE

PROTEIN INTERACTIONS Cancer Drug in the Pocket

The p53 pathway plays a pivotal role in the prevention of tumor development and has elicited considerable interest as a potential target for cancer drug discovery. In a systematic screen of synthetic chemicals, Vassilev et al. identified a series of small molecules (cis-imidazoline analogs, called "nutlins") that inhibit the interaction of p53 with MDM2, a protein that antagonizes p53's tumor suppressor function. The nutlins act by binding MDM2 within its p53-binding pocket, resulting in p53 activation in tumor cells with subsequent cell-cycle arrest and apoptosis. When orally administered to mice, the nutlins significantly inhibited tumor growth. These results validate the concept that small molecules targeting protein-protein interactions can be developed into effective therapeutics.

L. T. Vassilev, B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, E. A. Liu, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004). [Abstract] [Full Text]

Citation: Cancer Drug in the Pocket. Sci. STKE 2004, tw47 (2004).


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882